Table 4.
Associations between patient demographic and clinical characteristics and time on treatment
| Median TOT in Months (95% CI) | Crude HR (95% CI) | P | Adjusted HRa (95% CI) | P | |
|---|---|---|---|---|---|
| Age | |||||
| <60 years | 18.0 (4.3, 31.7) | Reference | 0.997 | ||
| ≥60 years | 11.0 (5.4, 16.6) | 1.0 (0.5, 2.1) | |||
| Smoking status | |||||
| Nonsmoker | 16.0 (7.4, 24.6) | Reference | 0.947 | ||
| Smoker or ex-smoker | 9.0 (<0.1, 19.3) | 1.7 (0.7, 4.2) | |||
| Comorbidities | |||||
| No | 18.0 (6.8, 29.2) | Reference | 0.922 | ||
| Yes | 16.0 (7.7, 24.3) | 1.0 (0.5, 2.1) | |||
| Histology | |||||
| Non-adenocarcinoma | 3.0 (—) | Reference | 0.302 | ||
| Adenocarcinoma | 16.0 (6.3, 25.7) | 0.5 (0.1, 2.0) | |||
| Stage at diagnosis | |||||
| III | 9.0 (<0.1, 20.8) | Reference | 0.760 | ||
| IV | 16.0 (6.6, 25.3) | 0.8 (0.2, 2.8) | |||
| ECOG score | |||||
| 0–1 | 14.0 (7.0,21.0) | Reference | 0.890 | Reference | 0.6 |
| 2–4 | NR | 0.9 (0.3, 2.7) | 1.3 (0.4, 4.1) | ||
| Type of treatment | |||||
| Chemotherapy | 2.0 (0.7, 3.3) | Reference | <0.01 | Reference | <0.01 |
| First-generation ALK inhibitor | 11.0 (1.6, 20.4) | 0.1 (0.04, 0.4) | 0.1 (0.05, 0.4) | ||
| Second-generation ALK inhibitor | NR | 0.05 (0.02, 0.2) | 0.06 (0.02, 0.2) | ||
| Treatment | |||||
| Chemotherapy | 2.0 (0.7, 3.3) | Reference | <0.01 | ||
| Crizotinib (first-generation) | 11.0 (8.0, 20.4) | 0.1 (0.04, 0.4) | |||
| Ceritinib (second-generation) | NR | 0.03 (0.01, 0.2) | |||
| Alectinib (second-generation) | NR | 0.07 (0.02, 0.2) |
Notes: aModel 1 variables: ECOG and type of treatment.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NR, median not reached (more than half were on treatment at the time of analysis); TOT, time on treatment.